TLR4-Myd88 pathway upregulated caveolin-1 expression contributes to coronary artery spasm

Xin Zhao,Jinfan Tian,Yue Liu,Zhishuai Ye,Mingyue Xu,Rongchong Huang,Xiantao Song
DOI: https://doi.org/10.1016/j.vph.2021.106947
IF: 5.738
2022-02-01
Vascular Pharmacology
Abstract:AIM: To study the role of toll-like receptors 4-myeloid differentiation factor 88 (TLR4-Myd88) dependent caveolin-1 (Cav-1) expression modulation in coronary artery spasm (CAS) and explore the underlying pathogenic mechanisms.METHODS AND RESULTS: Lipopolysaccharide (LPS) and acetylcholine (Ach) were used to develop the in vitro and in vivo models mimicking the physiological CAS microenvironment. LPS-induced upregulation of Cav-1 expression in mouse coronary and aorta endothelial cells was shown by western blot and immunofluorescence (IF) staining (p &lt; 0.01). Caveolin-1-knockout (Cav-1<sup>-/-</sup>) mice had reduced aortic inflammation after LPS challenge, and fewer ST segment changes were observed through electrocardiogram (ECG) monitoring compared to wild type mice after LPS and ACh administration. In vitro, pretreating human umbilical vein endothelial cells (HUVECs) with siCav-1 to knock down Cav-1 expression reduced the endothelial inflammation following LPS challenge. SiCav-1 also partially reversed the attenuated Ca<sup>2+</sup> concentration after LPS and ACh administration compared to the control group, which was evaluated by fluorescent molecular probing for Ca<sup>2+</sup> alternation monitoring (p &lt; 0.05). TLR4 and Myd88 downregulation by siRNA partially blocked the increased Cav-1 mRNA and protein expressions following LPS treatment, as well as partially reversed the decreased NO production evaluated by nitrate reductase method and the impaired Ca<sup>2+</sup> concentration of endothelial cells induced by LPS and ACh.CONCLUSION: These findings suggested that Cav-1, which was upregulated by TLR4-Myd88, served as an important modulator of CAS microenvironment establishment in vivo and in vitro, making it a potential pharmacologic target for the treatment of vasospasm via reduced endothelial cell inflammation.
pharmacology & pharmacy
What problem does this paper attempt to address?